Jim Simons’s Barinthus Biotherapeutics BRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-25,000
| Closed | -$16.5K | – | 3213 |
|
|
2026
Q2 | $16.5K | Sell |
25,000
-126,000
| -83% | -$82.1K | ﹤0.01% | 3106 |
|
|
2026
Q1 | $85.9K | Buy |
151,000
+7,900
| +6% | +$5.21K | ﹤0.01% | 3050 |
|
|
2025
Q4 | $100K | Buy |
143,100
+76,800
| +116% | +$76.7K | ﹤0.01% | 3014 |
|
|
2025
Q3 | $82.9K | Buy |
66,300
+30,000
| +83% | +$37.5K | ﹤0.01% | 3277 |
|
|
2025
Q2 | $33.8K | Buy |
36,300
+600
| +2% | +$524 | ﹤0.01% | 3429 |
|
|
2025
Q1 | $34.7K | Buy |
35,700
+600
| +2% | +$616 | ﹤0.01% | 3325 |
|
|
2024
Q4 | $42.4K | Buy |
35,100
+7,200
| +26% | +$8.38K | ﹤0.01% | 3411 |
|
|
2024
Q3 | $33.2K | Buy |
27,900
+2,800
| +11% | +$3.76K | ﹤0.01% | 3389 |
|
|
2024
Q2 | $35.1K | Sell |
25,100
-2,600
| -9% | -$5.87K | ﹤0.01% | 3324 |
|
|
2024
Q1 | $66K | Sell |
27,700
-1,999
| -7% | -$5.64K | ﹤0.01% | 3441 |
|
|
2023
Q4 | $110K | Buy |
29,699
+8,299
| +39% | +$28K | ﹤0.01% | 3282 |
|
|
2023
Q3 | $66K | Sell |
21,400
-12,600
| -37% | -$27.1K | ﹤0.01% | 3341 |
|
|
2023
Q2 | $70K | Buy |
34,000
+22,600
| +198% | +$53.5K | ﹤0.01% | 3549 |
|
|
2023
Q1 | $26K | Buy |
+11,400
| New | +$31.7K | ﹤0.01% | 3779 |
|
Other funds holding BRNS
Jim Simons's BRNS Position: Q3 2026 in Review
Jim Simons sold out of Barinthus Biotherapeutics (BRNS) in Q3 2026, closing a stake of 25,000 shares — an estimated $16.5K sold.
Jim Simons first reported a position in BRNS in Q1 2023 and held it in 14 quarters. The position peaked at $110K in Q4 2023. 1 fund tracked by Wall St. Rank holds BRNS as of Q3 2026.
- Jim Simons reported no remaining Barinthus Biotherapeutics position as of Q3 2026 after selling out during the quarter.
- Jim Simons sold 25,000 Barinthus Biotherapeutics shares in Q3 2026, an estimated $16.5K.
- Jim Simons first reported a position in Barinthus Biotherapeutics in Q1 2023 and held it in 14 quarters.
- Jim Simons's Barinthus Biotherapeutics position peaked at $110K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2026.
Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.